Name | 4-fluoropyridine hydrochloride |
Synonyms | 4-FLUOROPYRIDINE HCL 4-Fluoropyridine hyd 4-Fluoropyridine Hcl 4-Fluoropyridine HCl Salt 4-FLUOROPYRIDINE HYDROCHLORIDE 4-Fluoropyridine hydrochloride 4-fluoropyridine hydrochloride 4-fluoropyridine hydrochlorate |
CAS | 39160-31-1 |
EINECS | 630-984-2 |
InChI | InChI=1/C5H4FN.ClH/c6-5-1-3-7-4-2-5;/h1-4H;1H |
Molecular Formula | C5H5ClFN |
Molar Mass | 133.55 |
Melting Point | 100 °C |
Boling Point | 163.4°C at 760 mmHg |
Flash Point | 52.6°C |
Vapor Presure | 1.8mmHg at 25°C |
Appearance | Yellow powder |
Storage Condition | under inert gas (nitrogen or Argon) at 2-8°C |
MDL | MFCD00234055 |
Hazard Symbols | Xi - Irritant |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
WGK Germany | 3 |
HS Code | 29333990 |
introduction | 4-fluoropyridine hydrochloride is an organic intermediate, which can be prepared from 4-aminopyridine through diazotization reaction. |
preparation | the suspension of 4-aminopyridine (7.06g, 75.1 mmol) in 40 mL anhydrous dichloromethane was stirred at -78°C for 15 minutes, and added to anhydrous HF (31.2g, 1.6 mol). The reaction mixture was heated to -5°C, and NaNO2 (6.22g,90.1mmol) was added in batches within 10 minutes, while maintaining the temperature between -5 and 0°C. Let the mixture heat to room temperature, and then heat to 40-50 ° C 1.5 hours. Dichloromethane (50mL) was added. After cooling to -10 ℃, add 30% NH4OH aqueous solution dropwise within 10 minutes to adjust the pH to 10. Filtered demulsification, dichloromethane extraction. After drying on silica gel, bubble HCl gas through the solution. The solvent was evaporated in vacuum to obtain 4.9g(37.1mmol,50%) of light yellow salt. |
use | 4-fluoropyridine hydrochloride can be used to prepare Bub1 inhibitors with the following structure. Bub1 inhibitors should have therapeutic value in the treatment of proliferative conditions associated with increased uncontrolled proliferative cellular processes in warm-blooded animals such as humans, such as cancer, inflammation, arthritis, viral diseases, cardiovascular diseases, or fungal diseases. |